Genentech buys NASH biotech Jecure
Could antisense drug be a fatty liver disease blockbuster?
Regulator warns of death risk in patients on higher than recommended dose.
Mary Szela has quit to avoid a conflict of interest.
Genfit was among a group of NASH companies publishing updates at the International Liver Congress.